Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Modus Therapeutics appoints Ellen K. Donnelly, Ph.D. as CEO

Modus Therapeutics raises SEK 32 million to support further development of sevuparin for sickle cell disease

Learn more about our ongoing Phase 2 Study
SCD Therapeutics Conference, 2016

Modus colleagues presented our story at the 5th Annual Sickle Cell Disease Therapeutics conference in New York in October

Poster presented at ASH 2016
La Biotech Interview with Modus

Learn more about our study in the Middle East